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Abstract	  	  The	  past	  20	  years	  have	  heralded	  fascinating	  developments	  in	  the	  field	  of	  CTLA-­‐4	  biology.	  	  The	  CTLA-­‐4	  protein	  is	  a	  critical	  negative	  regulator	  of	  T	  cell	  immunity	  and	  its	  absence	  provokes	  severe	  lymphoproliferative	  disease.	  	  In	  a	  surprising	  twist,	  the	  generation	  of	  mixed	  bone	  marrow	  chimeric	  mice	  revealed	  that	  CTLA-­‐4	  predominantly	  functions	  in	  a	  cell-­‐extrinsic	  manner,	  suggesting	  that	  CTLA-­‐4	  expressed	  on	  one	  cell	  can	  modify	  the	  behaviour	  of	  another	  cell.	  	  This	  was	  followed	  by	  the	  demonstration	  that	  CTLA-­‐4	  is	  highly	  expressed	  in	  regulatory	  T	  cells	  and	  can	  contribute	  to	  their	  suppressive	  activity.	  In	  line	  with	  a	  cell-­‐extrinsic	  function,	  increasing	  evidence	  indicates	  that	  CTLA-­‐4-­‐positive	  cells	  can	  modify	  the	  phenotype	  of	  antigen	  presenting	  cells	  (APC),	  thereby	  regulating	  the	  priming	  of	  naive	  T	  cells.	  	  Notably,	  CTLA-­‐4	  is	  able	  to	  downregulate	  expression	  of	  costimulatory	  ligands	  on	  APC	  via	  a	  process	  of	  trans-­‐endocytosis.	  	  The	  identification	  of	  patients	  with	  mutations	  in	  the	  ctla4	  gene	  has	  provided	  an	  opportunity	  to	  study	  the	  contribution	  of	  CTLA-­‐4	  to	  Treg	  function	  and	  immune	  regulation	  in	  the	  human	  immune	  system.	  Finally,	  it	  has	  become	  apparent	  that	  CTLA-­‐4	  also	  plays	  a	  role	  in	  controlling	  humoral	  immunity,	  via	  the	  regulation	  of	  CD28-­‐driven	  follicular	  helper	  T	  cell	  differentiation.	  At	  the	  recent	  German	  Society	  for	  Immunology	  congress,	  I	  discussed	  some	  of	  the	  contributions	  of	  my	  own	  lab	  to	  the	  unfolding	  of	  the	  CTLA-­‐4	  story,	  in	  the	  context	  of	  the	  work	  of	  others	  in	  the	  field.	  	  Despite	  the	  enormous	  clinical	  potential	  associated	  with	  modulation	  of	  the	  CTLA-­‐4	  pathway,	  including	  the	  use	  of	  soluble	  CTLA-­‐4	  molecules	  in	  autoimmune	  settings	  and	  blocking	  antibodies	  in	  cancer,	  it	  is	  clear	  there	  is	  still	  much	  to	  learn	  about	  this	  important	  pathway.	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Introduction	  	  Understanding	  CTLA-­‐4-­‐based	  immunoregulation	  poses	  an	  unusual	  conceptual	  challenge.	  	  We	  are	  faced	  with	  a	  pair	  of	  homologous	  receptors	  expressed	  on	  T	  cells,	  CTLA-­‐4	  and	  CD28,	  that	  share	  the	  same	  ligands	  yet	  have	  completely	  opposing	  biological	  functions[1](Figure	  1).	  	  CD28	  is	  an	  important	  costimulatory	  molecule	  providing	  the	  critical	  "second	  signal"	  that	  permits	  full	  T	  cell	  activation;	  genetic	  deficiency	  of	  cd28	  therefore	  results	  in	  markedly	  impaired	  T	  cell	  immunity[2,	  3].	  	  Conversely,	  key	  experiments	  in	  the	  mid	  1990s	  established	  that	  ablation	  of	  the	  ctla4	  gene	  unleashes	  aggressive	  immune	  hyperactivation	  with	  multi-­‐organ	  lymphocytic	  infiltration	  and	  early	  death[4,	  5].	  	  Thus,	  the	  biological	  functions	  directed	  by	  CD28	  and	  CTLA-­‐4	  could	  not	  be	  more	  different.	  	  The	  notion	  that	  these	  two	  receptors	  share	  the	  same	  ligands,	  despite	  their	  polar	  opposite	  functions,	  is	  therefore	  somewhat	  counterintuitive.	  	  How	  can	  the	  same	  ligands	  safely	  direct	  both	  immunity	  and	  tolerance?	  	  	  	  The	  complexities	  of	  the	  system	  do	  not	  stop	  there.	  	  	  The	  striking	  phenotype	  of	  ctla4	  knockout	  mice	  highlights	  the	  importance	  of	  CTLA-­‐4	  inhibitory	  function,	  yet	  despite	  binding	  to	  cell	  surface	  ligands	  CTLA-­‐4	  appears	  surprisingly	  reluctant	  to	  present	  itself	  at	  the	  cell	  surface,	  instead	  spending	  the	  majority	  of	  its	  time	  in	  intracellular	  vesicles.	  	  Indeed,	  any	  CTLA-­‐4	  molecules	  reaching	  the	  cell	  membrane	  internalise	  again	  within	  minutes.	  	  This	  is	  no	  accident	  -­‐	  the	  constitutive	  endocytosis	  of	  CTLA-­‐4	  is	  hardwired	  via	  an	  amino	  acid	  sequence	  in	  its	  cytoplasmic	  tail,	  which	  contains	  a	  motif	  that	  couples	  it	  to	  the	  clathrin	  adaptor	  complex	  AP-­‐2[6-­‐8].	  	  The	  entire	  cytoplasmic	  sequence	  of	  CTLA-­‐4	  is	  highly	  conserved	  evolutionarily	  with	  virtually	  no	  deviations	  being	  tolerated	  in	  mammals	  -­‐	  your	  own	  CTLA-­‐4	  cytoplasmic	  sequence	  is	  100%	  identical	  to	  that	  found	  in	  mice	  and	  in	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dolphins.	  	  So,	  if	  you're	  wondering	  what	  you've	  got	  in	  common	  with	  Donald	  Trump	  (and	  Donald	  Duck?)	  -­‐	  it's	  probably	  your	  CTLA-­‐4.	  	  Why	  would	  such	  a	  critical	  immune	  regulator	  be	  so	  coy	  in	  making	  itself	  available	  for	  ligand	  engagement?	  How	  can	  the	  same	  ligands	  safely	  trigger	  both	  immunity	  via	  CD28	  and	  regulation	  via	  CTLA-­‐4?	  Clearly	  the	  CTLA-­‐4	  system	  represents	  a	  departure	  from	  normal	  immunological	  paradigms	  and	  new	  models	  must	  be	  invoked	  to	  fully	  understand	  it.	  	  	  	  
1.	  CTLA-­‐4	  functions	  in	  a	  cell	  extrinsic	  manner	  	  The	  late	  1990's	  was	  an	  exciting	  time	  for	  CTLA-­‐4	  research.	  	  We	  had	  embraced	  the	  idea	  of	  a	  "two-­‐signal	  model"	  of	  T	  cell	  activation,	  whereby	  triggering	  the	  TCR	  in	  the	  absence	  of	  CD28	  led	  to	  antigen-­‐specific	  unresponsiveness	  (clonal	  anergy)[9,	  10]	  -­‐	  suddenly	  it	  looked	  as	  though	  CTLA-­‐4	  might	  add	  an	  extra	  dimension	  to	  that	  model.	  	  Perhaps	  functional	  unresponsive	  was	  not	  a	  passive	  affair,	  arising	  from	  the	  absence	  of	  costimulation,	  but	  instead	  was	  being	  actively	  reinforced	  by	  an	  inhibitory	  receptor,	  namely	  CTLA-­‐4[11-­‐13].	  	  It	  looked	  increasingly	  as	  though	  the	  balance	  between	  CD28	  and	  CTLA-­‐4	  signaling	  was	  instrumental	  in	  dictating	  whether	  a	  T	  cell	  encounter	  with	  antigen	  was	  tolerogenic	  or	  immunogenic.	  	  Indeed,	  it	  was	  clear	  that	  the	  CD28	  and	  CTLA-­‐4	  pathways	  had	  completely	  opposite	  effects	  on	  the	  functional	  responses	  of	  T	  cells	  in	  
vitro[14-­‐18].	  	  Mechanistic	  data	  suggested	  that	  CTLA-­‐4	  might	  transmit	  signals	  via	  the	  tyrosine	  phosphatase	  SHP-­‐2[19,	  20]	  leading	  to	  inhibition	  of	  TCR-­‐mediated	  cellular	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activation	  by	  targeting	  the	  RAS	  pathway[19]	  or	  promoting	  TCR-­‐zeta	  dephosphorylation[20].	  	  Just	  as	  things	  seemed	  to	  be	  falling	  into	  place,	  the	  field	  was	  rocked	  by	  an	  extraordinary	  finding.	  	  Despite	  the	  fact	  that	  CTLA-­‐4-­‐deficient	  mice	  exhibited	  a	  lethal	  lymphoproliferative	  syndrome,	  bone	  marrow	  chimeras	  containing	  a	  mixture	  of	  wildtype	  and	  CTLA-­‐4-­‐deficient	  cells	  appeared	  to	  be	  completely	  normal.	  	  Not	  only	  were	  they	  healthy,	  but	  the	  CTLA-­‐4-­‐deficient	  T	  cells	  in	  them	  had	  a	  normal	  resting	  phenotype	  rather	  than	  a	  hyperactivated	  one[21](Figure	  2).	  	  This	  was	  hard	  to	  reconcile	  with	  the	  idea	  that	  CTLA-­‐4	  worked	  by	  transmitting	  inhibitory	  signals	  into	  the	  T	  cell	  expressing	  it	  -­‐	  in	  that	  case,	  the	  T	  cells	  bearing	  CTLA-­‐4	  would	  be	  appropriately	  regulated	  but	  those	  lacking	  it	  would	  not.	  	  This	  simple	  chimera	  experiment	  has	  since	  become	  something	  of	  an	  "elephant	  in	  the	  room"	  in	  the	  CTLA-­‐4	  field.	  	  Numerous	  mechanisms	  have	  been	  proposed	  whereby	  CTLA-­‐4	  controls	  the	  activation,	  adhesion	  or	  motility	  of	  the	  T	  cells	  expressing	  it.	  	  Yet	  the	  sequelae	  of	  these	  arguments	  is	  that	  CTLA-­‐4-­‐expressing	  cells	  in	  mixed	  bone	  marrow	  chimeras	  would	  be	  expected	  to	  exhibit	  altered	  activation,	  adhesion	  or	  motility,	  compared	  with	  the	  T	  cells	  lacking	  CTLA-­‐4.	  	  Why	  then	  is	  there	  no	  evidence	  of	  this?	  	  The	  bone	  marrow	  chimera	  experiment	  has	  been	  widely	  reproduced	  by	  multiple	  labs[22-­‐27]	  and	  in	  all	  cases	  CTLA-­‐4+/+	  cells	  efficiently	  prevent	  hyperactivation	  of	  CTLA-­‐4-­‐/-­‐	  cells.	  The	  chimeric	  mice	  have	  also	  been	  subjected	  to	  a	  range	  of	  parasitic[23]	  or	  viral[22,	  23]	  infections	  so	  that	  the	  biological	  response	  of	  the	  T	  cells	  to	  immunological	  challenge	  could	  be	  examined.	  In	  arguably	  the	  most	  comprehensive	  of	  these	  studies,	  antigen-­‐specific	  CD4	  and	  CD8	  T	  cell	  responses	  to	  8	  different	  viral	  epitopes	  were	  tracked.	  	  Antigen-­‐driven	  proliferation,	  acquisition	  of	  effector	  function,	  T	  cell	  repertoire	  selection,	  functional	  avidities,	  memory	  formation	  and	  response	  to	  re-­‐challenge	  were	  found	  to	  be	  essentially	  
	   6	  
indistinguishable	  between	  CTLA-­‐4-­‐deficient	  and	  CTLA-­‐4-­‐sufficient	  T	  cells	  in	  chimeric	  mice[22].	  	  	  Thus,	  there	  appears	  to	  be	  no	  detectable	  cell-­‐intrinsic	  consequence	  of	  expressing	  the	  CTLA-­‐4	  protein.	  	  Putative	  molecular	  mechanisms	  for	  CTLA-­‐4	  function	  must	  therefore	  take	  into	  account	  the	  strong	  evidence	  that	  CTLA-­‐4	  operates	  in	  a	  cell-­‐extrinsic	  manner	  in	  vivo.	  	  	  
2.	  Role	  of	  CTLA-­‐4	  in	  Treg	  function	  	  A	  cell-­‐extrinsic	  function	  for	  CTLA-­‐4	  implies	  that	  cells	  expressing	  CTLA-­‐4	  are	  able	  to	  regulate	  the	  behaviour	  of	  cells	  lacking	  CTLA-­‐4.	  	  One	  obvious	  paradigm	  of	  cell-­‐extrinsic	  regulation	  is	  the	  control	  of	  the	  immune	  system	  by	  regulatory	  T	  cells	  (Treg).	  This	  specialised	  subset	  of	  CD4	  T	  cells	  acts	  in	  a	  dominant	  suppressive	  manner	  to	  inhibit	  the	  induction	  of	  autoimmune	  diseases[28,	  29].	  	  	  Mice	  lacking	  Treg,	  due	  to	  a	  defect	  in	  the	  transcription	  factor	  Foxp3,	  develop	  a	  lethal	  lymphoproliferative	  disorder	  highly	  reminiscent	  of	  that	  seen	  in	  CTLA-­‐4	  deficiency[30-­‐32]	  and	  humans	  with	  mutations	  in	  Foxp3	  also	  exhibit	  an	  aggressive	  immune	  dysregulation	  syndrome[33,	  34].	  	  It	  therefore	  caused	  great	  excitement	  when	  it	  was	  shown	  that	  Treg	  are	  the	  major	  cell	  population	  expressing	  CTLA-­‐4[35,	  36].	  	  CTLA-­‐4	  is	  constitutively	  expressed	  intracellularly	  at	  high	  levels	  in	  the	  Treg	  population	  but	  is	  lacking	  from	  naive	  conventional	  T	  cells	  and	  is	  only	  induced	  de	  novo	  following	  cellular	  activation.	  	  These	  observations	  prompted	  intense	  speculation	  over	  whether	  CTLA-­‐4	  is	  responsible	  for	  mediating	  the	  suppressive	  function	  of	  Treg.	  	  However,	  testing	  this	  idea	  experimentally	  proved	  surprisingly	  difficult.	  	  Attempts	  to	  block	  the	  function	  of	  Treg	  with	  CTLA-­‐4	  antibodies	  in	  vitro	  produced	  mixed	  results,	  with	  some	  studies	  demonstrating	  reduced	  Treg	  suppression[36,	  37]	  and	  some	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not[29].	  	  In	  one	  study,	  different	  preparations	  of	  the	  same	  antibody	  clone	  yielded	  differing	  results[38].	  	  When	  Treg	  from	  CTLA-­‐4-­‐deficient	  mice	  were	  used,	  these	  generally	  exhibited	  suppressive	  function	  in	  vitro,	  sometimes	  as	  efficiently	  as	  wildtype	  Treg[37,	  39,	  40]	  and	  sometimes	  slightly	  less	  so[36].	  	  A	  major	  confounder	  for	  many	  of	  these	  studies	  was	  that	  the	  CTLA-­‐4-­‐deficient	  Treg	  were	  being	  isolated	  from	  mice	  that	  were	  in	  the	  process	  of	  developing	  lymphoproliferative	  disease.	  	  Since	  disease	  in	  CTLA-­‐4-­‐deficient	  mice	  results	  from	  unimpinged	  engagement	  of	  the	  CD28	  pathway,	  it	  can	  be	  abrogated	  by	  blocking	  CD28	  signaling[41-­‐43],	  theoretically	  removing	  this	  confounder.	  	  However	  the	  known	  requirement	  of	  CD28	  for	  normal	  Treg	  generation	  and	  homeostasis[44,	  45]	  poses	  a	  limitation	  here:	  to	  specifically	  test	  to	  role	  of	  CTLA-­‐4	  in	  Treg,	  ideally	  one	  would	  want	  to	  interrupt	  CTLA-­‐4	  pathway	  whilst	  leaving	  the	  CD28	  pathway	  intact.	  	  Around	  the	  time	  that	  these	  issues	  were	  being	  debated,	  my	  group	  was	  studying	  double	  transgenic	  mice	  expressing	  ovalbumin	  (OVA)	  in	  the	  pancreas	  under	  the	  rat	  insulin	  promoter	  and	  also	  expressing	  the	  OVA-­‐specific	  TCR	  transgene,	  DO11.10.	  	  This	  model	  was	  not	  originally	  intended	  to	  be	  used	  for	  Treg	  analysis	  but	  rather	  was	  designed	  to	  study	  the	  early	  events	  in	  type	  1	  diabetes	  pathogenesis.	  	  However,	  as	  is	  often	  the	  case	  in	  science,	  unexpected	  findings	  can	  open	  the	  door	  to	  new	  insights.	  	  Realising	  that	  the	  rat	  insulin	  promoter	  was	  active	  in	  the	  thymus,	  and	  that	  by	  driving	  expression	  of	  OVA	  at	  this	  site	  it	  was	  triggering	  Treg	  differentiation[46],	  we	  began	  to	  consider	  the	  potential	  advantages	  of	  having	  a	  TCR	  transgenic	  model	  of	  Treg	  differentiation.	  	  Most	  notable	  among	  these	  was	  the	  idea	  that	  by	  breeding	  these	  animals	  to	  a	  CTLA-­‐4	  deficient	  strain	  we	  would	  be	  able	  to	  generate	  antigen-­‐specific	  Treg	  that	  lacked	  CTLA-­‐4	  but	  retained	  an	  intact	  CD28	  pathway.	  	  To	  avoid	  any	  variation	  in	  the	  antigen	  specificity	  of	  the	  Treg,	  we	  bred	  the	  mice	  to	  a	  rag	  deficient	  background	  (precluding	  expression	  of	  endogenous	  TCR-­‐
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α	  chains).	  This	  had	  the	  added	  advantage	  of	  avoiding	  any	  residual	  off-­‐target	  activation	  of	  the	  CTLA-­‐4	  deficient	  T	  cells,	  since	  now	  their	  specificity	  was	  strictly	  restricted	  to	  the	  ovalbumin	  expressed	  in	  the	  pancreatic	  islets.	  	  	  	  For	  the	  first	  time	  we	  were	  able	  to	  test	  the	  suppressive	  function	  of	  CTLA-­‐4-­‐deficient	  Treg	  bearing	  an	  identical	  specificity	  and	  affinity	  for	  antigen	  as	  their	  wildtype	  counterparts	  (both	  being	  DO11.10+rag-­‐/-­‐),	  that	  had	  an	  intact	  CD28	  pathway,	  and	  that	  had	  not	  been	  isolated	  from	  mice	  with	  lymphoproliferative	  disease.	  	  By	  purifying	  OVA-­‐specific	  Treg	  from	  CTLA-­‐4-­‐sufficient	  or	  CTLA-­‐4-­‐deficient	  mice	  we	  were	  able	  to	  demonstrate	  that	  CTLA-­‐4	  expression	  was	  absolutely	  required	  for	  regulation	  of	  the	  autoimmune	  response	  against	  pancreatic	  islets	  in	  vivo[40]	  (Figure	  3).	  	  This	  contrasted	  with	  the	  results	  obtained	  in	  vitro	  using	  the	  same	  Treg	  populations[40],	  suggesting	  that	  in	  vitro	  suppression	  assays	  do	  not	  always	  faithfully	  recapitulate	  in	  vivo	  scenarios.	  	  A	  similar	  message	  came	  from	  the	  work	  of	  Sojka	  et	  al[39]	  who	  found	  that	  CTLA-­‐4	  deficient	  Treg	  were	  incapable	  of	  suppressing	  lymphopenia-­‐induced	  T	  cell	  expansion	  in	  vivo	  despite	  showing	  intact	  suppressive	  function	  in	  vitro.	  The	  seminal	  experiment	  from	  this	  era,	  which	  put	  the	  role	  of	  CTLA-­‐4	  in	  Treg	  function	  beyond	  doubt,	  was	  the	  demonstration	  by	  the	  Sakaguchi	  lab	  that	  mice	  selectively	  lacking	  CTLA-­‐4	  expression	  in	  Treg	  succumbed	  to	  a	  spontaneous	  lymphoproliferation	  with	  fatal	  T	  cell-­‐dependent	  autoimmune	  disease[47].	  	  In	  fact,	  mice	  lacking	  CTLA-­‐4	  in	  Treg	  only	  survived	  a	  few	  weeks	  longer	  than	  mice	  lacking	  CTLA-­‐4	  systemically.	  	  This	  marked	  a	  change	  in	  direction	  for	  the	  CTLA-­‐4	  field	  that,	  in	  some	  ways,	  was	  as	  significant	  as	  the	  original	  description	  of	  the	  knockout	  mice.	  	  It	  was	  now	  clear	  that	  a	  major	  role	  of	  CTLA-­‐4	  related	  to	  its	  ability	  to	  function	  in	  the	  regulatory	  T	  cell	  population.	  	  Indeed,	  transgenic	  expression	  of	  CTLA-­‐4	  was	  later	  shown	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to	  be	  one	  of	  three	  core	  requirements	  to	  convert	  a	  conventional	  CD4	  T	  cell	  into	  a	  "homemade"	  regulatory	  T	  cell[48].	  	  Another	  key	  message	  to	  arise	  from	  this	  era	  was	  the	  notion	  that	  there	  is	  a	  degree	  of	  redundancy	  in	  Treg	  suppressive	  mechanisms.	  	  For	  example	  it	  was	  shown	  that	  while	  wildtype	  Treg	  used	  CTLA-­‐4	  to	  suppress	  colitis,	  Treg	  lacking	  the	  CTLA-­‐4	  molecule	  were	  able	  to	  utilise	  IL-­‐10	  to	  achieve	  the	  same	  end[24].	  	  Likewise,	  the	  function	  of	  CTLA-­‐4	  deficient	  Treg	  was	  shown	  to	  be	  partially	  TGF-­‐β	  dependent	  in	  a	  separate	  study[37],	  suggesting	  that,	  like	  IL-­‐10,	  TGF-­‐β	  can	  also	  compensate	  to	  some	  extent	  for	  a	  lack	  of	  CTLA-­‐4.	  	  	  Together	  the	  experimental	  work	  indicated	  that	  the	  CTLA-­‐4	  pathway	  is	  an	  important	  component	  of	  Treg	  suppressive	  function,	  but	  that	  Treg	  also	  have	  other	  tools	  at	  their	  disposal	  to	  maintain	  immune	  homeostasis[49,	  50].	  	  It	  is	  likely,	  therefore,	  that	  the	  relative	  importance	  of	  any	  given	  suppressive	  mechanism	  varies	  depending	  on	  the	  physiological	  context	  of	  the	  immune	  response	  being	  regulated.	  	  	  
3.	  CTLA-­‐4	  and	  the	  modification	  of	  APC	  phenotype	  	  Given	  that	  CTLA-­‐4	  appeared	  to	  comprise	  an	  important	  effector	  molecule	  for	  Treg	  suppression[51],	  this	  raised	  the	  question	  of	  how	  this	  might	  work	  at	  a	  molecular	  level.	  	  Models	  based	  on	  CTLA-­‐4-­‐dependent	  inhibition	  of	  TCR-­‐mediated	  signaling	  were	  not	  useful	  in	  this	  context,	  since	  Treg	  require	  TCR	  signaling	  to	  elicit	  suppressive	  function[28,	  52,	  53].	  A	  common	  theme	  that	  began	  to	  emerge	  from	  the	  literature	  was	  that	  CTLA-­‐4-­‐expressing	  cells	  were	  able	  to	  modify	  the	  phenotype	  of	  antigen	  presenting	  cells.	  	  Early	  data	  suggested	  that	  this	  might	  reflect	  reverse-­‐signaling	  by	  CD80/CD86	  leading	  to	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activation	  of	  the	  enzyme	  indoleamine	  2,3-­‐dioxygenase	  (IDO)[54,	  55].	  However	  this	  hypothesis	  was	  challenged	  by	  transcriptional	  profiling	  analysis	  that	  failed	  to	  identify	  gene	  expression	  changes	  in	  CD80/CD86	  expressing	  cells	  after	  treatment	  with	  soluble	  CTLA-­‐4	  fusion	  proteins	  (including	  abatacept	  and	  belatacept)[56].	  	  Furthermore,	  it	  was	  shown	  that	  abatacept	  inhibits	  T	  cell	  proliferation	  without	  increasing	  expression	  of	  IDO[57],	  consistent	  with	  a	  role	  for	  CTLA-­‐4	  in	  limiting	  CD28	  engagement	  via	  binding	  to	  their	  shared	  ligands,	  rather	  than	  triggering	  the	  IDO	  pathway.	  	  In	  addition,	  CTLA-­‐4	  blockade	  was	  even	  more	  effective	  in	  IDO	  deficient	  mice	  than	  wildtype	  mice[58],	  an	  observation	  that	  is	  hard	  to	  reconcile	  with	  the	  notion	  that	  CTLA-­‐4	  operates	  via	  IDO	  induction.	  	  An	  independent	  observation	  that	  began	  to	  gain	  traction	  in	  the	  field	  was	  that	  Treg	  expressing	  CTLA-­‐4	  were	  able	  to	  downregulate	  expression	  of	  CD86	  and	  CD80	  on	  antigen	  presenting	  cells[47,	  59-­‐63].	  My	  group	  first	  noted	  this	  in	  experiments	  performed	  in	  vitro	  with	  murine	  Treg	  and	  splenic	  dendritic	  cells,	  where	  we	  observed	  a	  marked	  downregulation	  of	  CD86	  (but	  not	  MHC	  class	  II)	  that	  could	  be	  inhibited	  by	  anti-­‐CTLA-­‐4	  antibodies[40].	  	  In	  collaboration	  with	  David	  Sansom's	  lab,	  across	  the	  hall,	  we	  were	  able	  to	  identify	  a	  molecular	  mechanism	  for	  the	  observed	  CTLA-­‐4-­‐mediated	  ligand	  downregulation.	  	  Through	  an	  extensive	  series	  of	  experiments	  in	  transfectant	  systems,	  primary	  cells,	  and	  ultimately	  in	  vivo	  models,	  we	  were	  able	  to	  show	  that	  CTLA-­‐4	  was	  capable	  of	  removing	  its	  ligands	  from	  adjacent	  cells	  by	  a	  process	  of	  trans-­‐endocytosis[64].	  	  Using	  our	  TCR-­‐transgenic	  Treg	  system,	  we	  showed	  that	  Treg	  were	  able	  to	  capture	  GFP-­‐tagged	  costimulatory	  ligands	  from	  APC	  in	  an	  antigen-­‐dependent	  manner	  
in	  vivo.	  	  Importantly,	  however	  CTLA-­‐4	  deficient	  Treg,	  which	  lacked	  regulatory	  capacity	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in	  the	  adoptive	  transfer	  model	  of	  diabetes[40],	  were	  unable	  to	  capture	  costimulatory	  ligands	  in	  vivo[64].	  	  	  The	  description	  of	  CTLA-­‐4-­‐mediated	  trans-­‐endocytosis	  changed	  our	  perspective	  on	  the	  entire	  biology	  of	  the	  CTLA-­‐4	  pathway.	  	  Suddenly	  the	  highly	  endocytic	  behaviour	  of	  the	  CTLA-­‐4	  molecule	  made	  sense	  -­‐	  we	  now	  saw	  it	  as	  a	  molecular	  pump	  efficiently	  capturing	  ligands	  from	  the	  surface	  of	  opposing	  cells,	  trafficking	  them	  to	  lysosomes	  for	  degradation,	  then	  recycling	  to	  repeat.	  	  Similarly	  the	  sharing	  of	  ligands	  between	  CTLA-­‐4	  and	  CD28	  seemed	  far	  more	  logical	  if	  the	  purpose	  of	  CTLA-­‐4	  was	  to	  strip	  APCs	  of	  costimulatory	  ligands,	  thereby	  limiting	  CD28	  engagement,	  rather	  than	  to	  transmit	  inhibitory	  signals[65].	  	  The	  conundrum	  of	  how	  ligands	  "decided"	  whether	  to	  positively	  signal	  via	  CD28	  or	  negatively	  signal	  via	  CTLA-­‐4	  was	  instantly	  removed.	  	  	  	  The	  notion	  that	  CTLA-­‐4	  functioned	  as	  a	  ligand	  competitor	  to	  regulate	  CD28	  signaling	  was	  not	  new,	  and	  in	  fact	  was	  one	  of	  the	  earliest	  postulated	  mechanisms	  of	  action	  for	  CTLA-­‐4	  based	  on	  its	  superior	  affinity[66].	  	  Trans-­‐endocytosis	  effectively	  "supercharged"	  this	  concept:	  rather	  than	  costimulatory	  ligands	  being	  fleetingly	  blocked	  during	  a	  brief	  foray	  of	  a	  CTLA-­‐4	  molecule	  to	  the	  cell	  surface,	  instead	  CTLA-­‐4	  removed	  the	  ligands	  altogether	  from	  the	  APC	  and	  chaperoned	  them	  to	  lysosomes	  for	  degradation	  (Figure	  4).	  	  Factor	  in	  the	  ability	  of	  the	  same	  CTLA-­‐4	  molecule	  to	  re-­‐cycle	  to	  the	  surface	  for	  more,	  and	  we	  were	  now	  faced	  with	  a	  highly	  efficient	  system	  for	  limiting	  access	  of	  CD28	  to	  costimulatory	  ligands.	  	  	  Intriguingly,	  the	  key	  motif	  in	  the	  CTLA-­‐4	  cytoplasmic	  tail	  that	  confers	  endocytic	  behaviour,	  YVKM,	  is	  conserved	  in	  mammals	  and	  birds	  but	  not	  in	  species	  that	  are	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evolutionarily	  more	  primitive.	  	  Accordingly	  trout	  CTLA-­‐4	  is	  not	  subject	  to	  clathrin-­‐mediated	  endocytosis	  and	  predominantly	  exists	  as	  a	  cell	  surface	  protein[67].	  	  It	  is	  therefore	  plausible	  that	  CTLA-­‐4	  originally	  operated	  in	  a	  cell-­‐intrinsic	  manner,	  as	  a	  cell	  surface	  competitor	  to	  limit	  CD28	  ligand	  binding,	  until	  the	  emergence	  of	  an	  intracellular	  trafficking	  motif	  took	  its	  function	  to	  the	  next	  level.	  	  	  
4.	  Humans	  with	  CTLA-­‐4	  deficiency	  	  	  Perhaps	  the	  most	  unexpected	  development	  in	  our	  CTLA-­‐4	  journey	  was	  the	  fortuitous	  identification	  of	  patients	  with	  heterozgous	  CTLA-­‐4	  deficiency	  in	  our	  local	  CVID	  clinic,	  in	  collaboration	  with	  the	  Grimbacher	  and	  Sansom	  labs[68].	  	  Of	  all	  the	  places	  we	  would	  have	  expected	  individuals	  with	  CTLA-­‐4	  deficiency	  to	  present,	  an	  immunodeficiency	  clinic	  was	  the	  last	  on	  the	  list.	  	  However,	  autoimmunity	  and	  immunodeficiency	  are	  strangely	  compatible	  bedfellows,	  both	  being	  manifestations	  of	  immune	  dysregulation.	  After	  all,	  normal	  immune	  homeostasis	  relies	  on	  a	  complex	  series	  of	  feedback	  mechanisms,	  with	  positive	  and	  negative	  regulation	  of	  the	  immune	  system	  being	  closely	  interlinked.	  Impaired	  immune	  responsiveness	  can	  compromise	  regulation	  (for	  example,	  reduced	  IL-­‐2	  production	  from	  conventional	  T	  cells	  impacts	  on	  Treg	  homeostasis)	  and	  conversely	  impaired	  Treg	  function	  can	  compromise	  protective	  immunity[69,	  70].	  	  Epitomising	  this	  paradox,	  patients	  with	  CTLA-­‐4	  mutations	  exhibited	  diverse	  symptoms	  of	  autoimmunity	  (including	  autoimmune	  cytopenias,	  arthritis,	  thyroiditis,	  enteropathy	  and	  lymphadenopathy)	  yet	  showed	  a	  high	  incidence	  of	  hypogammaglobulinemia	  associated	  with	  a	  gradual	  loss	  of	  peripheral	  B	  cells.	  	  The	  link	  between	  hyperactivation	  of	  the	  T	  cell	  compartment	  and	  B	  cell	  attrition	  is	  currently	  unclear.	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  Flow	  cytometric	  staining	  revealed	  that	  the	  Treg	  isolated	  from	  individuals	  with	  CTLA-­‐4	  mutations	  had	  decreased	  CTLA-­‐4	  expression	  and	  this	  was	  particularly	  marked	  following	  a	  brief	  period	  of	  in	  vitro	  restimulation.	  	  Furthermore,	  these	  Treg	  were	  impaired	  in	  their	  capacity	  to	  trans-­‐endocytose	  costimulatory	  ligands	  and	  to	  elicit	  suppressive	  function	  in	  
in	  vitro	  assays[68].	  	  Analysis	  of	  an	  independent	  cohort	  of	  patients	  with	  CTLA-­‐4	  mutations	  at	  the	  NIH	  also	  revealed	  decreased	  CTLA-­‐4	  expression	  and	  reduced	  Treg	  function[71].	  	  	  While	  the	  full	  clinical	  phenotype	  of	  this	  patient	  cohort	  is	  still	  emerging[68,	  71-­‐73],	  CTLA-­‐4	  heterozygous	  individuals	  have	  provided	  the	  first	  genetic	  evidence	  that	  CTLA-­‐4	  is	  an	  important	  component	  of	  Treg	  function	  and	  immune	  regulation	  in	  humans.	  	  	  
5.	  CTLA-­‐4	  and	  Treg	  homeostasis	  	  In	  addition	  to	  contributing	  to	  Treg	  suppressive	  function,	  there	  is	  also	  evidence	  that	  CTLA-­‐4	  controls	  Treg	  homeostasis.	  We	  and	  others	  found	  that	  CTLA-­‐4	  knockout	  mice	  exhibit	  a	  dramatically	  expanded	  Treg	  population	  that	  show	  increased	  expression	  of	  the	  proliferation	  marker	  Ki67[40,	  47].	  	  This	  phenotype	  is	  recapitulated	  by	  inducible	  deletion	  of	  CTLA-­‐4	  in	  adult	  mice[74,	  75]	  and	  in	  line	  with	  this,	  treatment	  of	  wildtype	  mice	  with	  blocking	  anti-­‐CTLA-­‐4	  antibody	  augments	  Treg	  numbers	  in	  lymphoid	  tissues[76,	  77].	  	  Proliferation	  and	  expansion	  of	  Treg	  has	  also	  been	  reported	  in	  humans	  treated	  with	  anti-­‐CTLA-­‐4	  antibody[78]	  and	  Treg	  percentages	  are	  higher	  in	  some,	  but	  not	  all,	  individuals	  with	  CTLA-­‐4	  mutations	  [Hou	  et	  al	  Blood,	  in	  revision].	  The	  fact	  that	  Treg	  can	  present	  in	  higher	  numbers	  in	  settings	  where	  they	  have	  been	  deprived	  of	  a	  key	  suppressive	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mechanism	  highlights	  that	  a	  simple	  assessment	  of	  Treg	  number	  can	  be	  a	  poor	  proxy	  for	  gauging	  the	  level	  of	  immune	  regulation.	  	  The	  proliferation	  of	  Treg	  is	  known	  to	  be	  positively	  regulated	  by	  CD28	  signaling[44,	  45]	  suggesting	  a	  model	  in	  which	  CTLA-­‐4	  regulates	  Treg	  proliferation	  by	  controlling	  access	  of	  CD28	  to	  their	  shared	  ligands	  (CD80	  and	  CD86).	  	  This	  fits	  with	  clear	  evidence	  that	  the	  biological	  role	  of	  CTLA-­‐4	  is	  regulate	  the	  CD28	  pathway:	  accordingly	  mice	  that	  lack	  CTLA-­‐4	  but	  also	  lack	  CD28[43],	  or	  CD80/86[42],	  do	  not	  exhibit	  any	  signs	  of	  immune	  hyperactivation.	  	  Likewise,	  experimental	  blockade	  of	  CD80	  and	  CD86	  with	  a	  CTLA-­‐4-­‐Ig	  fusion	  protein	  or	  anti-­‐CD80	  and	  anti-­‐CD86	  antibodies	  also	  abrogates	  disease	  in	  CTLA-­‐4-­‐deficient	  mice[37,	  79].	  It	  is	  known	  that	  Treg	  turn	  over	  to	  a	  higher	  extent	  than	  Tconv[46,	  80-­‐83],	  most	  likely	  reflecting	  their	  continuous	  encounter	  with	  self-­‐antigens.	  	  Indeed	  antigen-­‐specific	  Treg	  are	  known	  to	  accumulate	  in	  the	  lymph	  nodes	  draining	  the	  tissue	  site	  where	  their	  antigen	  is	  expressed[46],	  perhaps	  explaining	  why	  the	  Treg	  TCR	  repertoire	  varies	  by	  anatomical	  location[84].	  Collectively,	  this	  indicates	  that	  local	  Treg	  homoestasis	  is	  shaped	  both	  by	  antigenic	  availability	  and	  by	  encounter	  with	  CD80/86	  ligands,	  the	  latter	  being	  regulated	  by	  CTLA-­‐4.	  	  
6.	  Function	  of	  CTLA-­‐4	  in	  conventional	  T	  cells	  	  A	  considerable	  body	  of	  evidence,	  from	  both	  mouse	  and	  human,	  supported	  a	  major	  role	  for	  CTLA-­‐4	  in	  the	  Treg	  compartment.	  	  However,	  one	  conundrum	  that	  continued	  to	  trouble	  us	  was	  that	  CTLA-­‐4	  was	  known	  to	  function,	  albeit	  in	  a	  limited	  manner,	  in	  conventional	  T	  cells	  (Tconv)	  too.	  That	  being	  the	  case,	  why	  did	  CTLA-­‐4	  deficient	  Tconv	  behave	  identically	  to	  CTLA-­‐4	  sufficient	  Tconv	  in	  the	  mixed	  bone	  marrow	  chimeric	  mice	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discussed	  in	  section	  1?	  	  Surely	  if	  CTLA-­‐4	  was	  operating	  in	  the	  Tconv	  compartment,	  there	  should	  be	  a	  discernable	  functional	  consequence	  of	  this.	  	  We	  reasoned	  that	  a	  potential	  explanation	  for	  this	  paradox	  could	  be	  that	  CTLA-­‐4	  operates	  in	  a	  cell-­‐extrinsic,	  rather	  than	  cell-­‐intrinsic,	  manner	  in	  Tconv.	  	  	  	  To	  test	  this	  hypothesis,	  we	  set	  up	  a	  model	  in	  which	  OVA-­‐specific	  conventional	  T	  cells	  (that	  were	  exclusively	  Foxp3-­‐negative)	  were	  adoptively	  transferred	  into	  mice	  expressing	  OVA	  in	  the	  pancreas,	  allowing	  us	  to	  track	  the	  T	  cell	  response	  to	  antigen	  in	  the	  pancreatic	  lymph	  node.	  CTLA-­‐4	  deficient	  Tconv	  proliferated	  to	  a	  greater	  extent	  than	  CTLA-­‐4	  sufficient	  Tconv	  in	  this	  setting,	  highlighting	  that	  under	  certain	  conditions	  CTLA-­‐4	  expressed	  in	  conventional	  T	  cells	  can	  regulate	  immune	  responsiveness.	  	  We	  next	  asked	  the	  key	  question	  -­‐	  is	  CTLA-­‐4	  function	  in	  Tconv	  a	  cell-­‐intrinsic	  or	  cell-­‐extrinsic	  phenomenon?	  	  By	  co-­‐transferring	  a	  mixture	  of	  wildtype	  and	  CTLA-­‐4	  deficient	  Tconv,	  identifiable	  on	  the	  basis	  of	  congenic	  markers,	  we	  were	  able	  to	  distinguish	  between	  these	  possibilities.	  	  Strikingly	  we	  found	  that	  CTLA-­‐4-­‐deficient	  Tconv	  no	  longer	  proliferated	  more	  than	  CTLA-­‐4-­‐sufficient	  Tconv	  if	  the	  two	  populations	  were	  co-­‐transferred[85].	  	  In	  fact,	  it	  appeared	  as	  though	  the	  CTLA-­‐4-­‐sufficient	  cells	  were	  "regulating"	  the	  CTLA-­‐4	  deficient	  ones.	  	  This	  regulatory	  behaviour	  was	  not	  associated	  with	  upregulation	  of	  the	  Treg-­‐associated	  transcription	  factor	  Foxp3	  in	  the	  T	  cells.	  	  Thus	  CTLA-­‐4	  appeared	  to	  operate	  in	  a	  cell-­‐extrinsic	  "regulatory"	  manner,	  even	  when	  expressed	  in	  the	  conventional	  T	  cell	  compartment.	  	  Together	  with	  a	  similar	  study	  from	  the	  Alison	  lab[86],	  these	  findings	  resolved	  the	  paradox	  of	  why	  cell	  intrinsic	  functions	  of	  CTLA-­‐4	  are	  not	  apparent	  in	  mixed	  bone	  marrow	  chimeric	  mice.	  	  In	  other	  words,	  for	  both	  Treg	  and	  Tconv,	  CTLA-­‐4	  is	  not	  operating	  directly	  on	  the	  cell	  expressing	  it	  but	  instead	  is	  working	  indirectly	  such	  that	  CTLA-­‐4+	  cells	  modify	  the	  responses	  of	  CTLA-­‐4-­‐	  cells.	  	  Since	  Tconv,	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like	  Treg,	  can	  use	  CTLA-­‐4	  to	  perform	  trans-­‐endocytosis[64],	  it	  seems	  likely	  that	  CTLA-­‐4	  operates	  by	  modifying	  APC	  phenotype	  regardless	  of	  the	  cell	  type	  it	  is	  expressed	  in.	  	  	  Of	  note,	  while	  CTLA-­‐4	  is	  clearly	  able	  to	  operate	  in	  the	  conventional	  T	  cell	  compartment,	  all	  of	  our	  experience	  suggests	  the	  major	  function	  of	  CTLA-­‐4	  is	  in	  Treg.	  	  In	  fact,	  to	  reveal	  the	  function	  Tconv-­‐expressed	  CTLA-­‐4	  in	  vivo	  it	  is	  often	  necessary	  to	  remove	  or	  inactivate	  Treg,	  since	  the	  dominant	  role	  of	  CTLA-­‐4	  in	  this	  population	  can	  mask	  its	  more	  subtle	  role	  in	  Tconv.	  	  It	  is	  tempting	  to	  speculate	  that	  the	  evolution	  of	  Foxp3	  and	  Treg	  cells[87,	  88],	  coincident	  with	  the	  evolution	  of	  CTLA-­‐4	  endocytosis,	  permitted	  a	  previously	  cell-­‐intrinsic	  mechanism	  of	  regulation	  to	  be	  outsourced	  to	  dedicated	  cell	  population	  for	  use	  in	  a	  cell-­‐extrinsic	  manner.	  	  As	  a	  result,	  Treg	  wield	  CTLA-­‐4	  like	  true	  professionals	  and	  are	  the	  dominant	  vehicle	  for	  CTLA-­‐4-­‐mediated	  immune	  regulation,	  although,	  if	  need	  be,	  conventional	  T	  cells	  can	  still	  employ	  it	  to	  temper	  clone	  size.	  	  	  
7.	  CTLA-­‐4	  regulates	  follicular	  helper	  T	  cell	  differentiation	  	  In	  the	  trans-­‐endocytosis	  model,	  CTLA-­‐4-­‐dependent	  removal	  of	  costimulatory	  ligands	  from	  APC	  serves	  to	  limit	  T	  cell	  CD28	  engagement.	  Thus,	  the	  key	  downstream	  consequence	  of	  CTLA-­‐4	  function	  is	  a	  quantitative	  alteration	  of	  CD28	  signaling.	  	  In	  this	  view,	  CD28	  knockout	  and	  CTLA-­‐4	  knockout	  mice	  represent	  two	  extreme	  ends	  of	  the	  same	  spectrum,	  presenting	  phenotypes	  of	  defective	  and	  excessive	  CD28	  triggering	  respectively.	  	  In	  this	  regard,	  we	  recently	  noted	  that	  T	  cells	  in	  CTLA-­‐4-­‐deficient	  mice	  undergo	  spontaneous	  differentiation	  into	  follicular	  helper	  T	  cells	  (Tfh),	  a	  subset	  known	  to	  be	  dependent	  on	  CD28	  signaling.	  	  Tfh	  cells	  support	  the	  fine-­‐tuning	  of	  B	  cell	  antibody	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responses	  within	  specialised	  structures	  termed	  germinal	  centers	  and	  it	  has	  been	  shown	  previously	  that	  CD28	  deficient	  T	  cells	  are	  unable	  to	  differentiate	  into	  Tfh[89]	  and	  support	  germinal	  center	  formation[90,	  91].	  	  The	  overproduction	  of	  Tfh	  in	  CTLA-­‐4	  deficient	  mice	  extends	  these	  observations	  by	  suggesting	  that	  increasing	  the	  level	  of	  CD28	  engagement	  triggers	  a	  quantitative	  increase	  in	  Tfh	  differentiation.	  	  In	  other	  words,	  it's	  not	  simply	  that	  CD28	  is	  needed	  for	  Tfh,	  but	  instead	  the	  amount	  of	  CD28	  engagement	  is	  directly	  coupled	  to	  the	  extent	  of	  Tfh	  differentation.	  	  Consistent	  with	  this	  notion,	  increasing	  CD28	  engagement	  (by	  blocking	  CTLA-­‐4)	  was	  sufficient	  to	  trigger	  spontaneous	  Tfh	  differentiation	  in	  wildtype	  mice:	  conversely,	  limiting	  CD28	  engagement	  by	  using	  naive	  T	  cells	  from	  a	  CD28	  heterozygous	  donor	  resulted	  in	  a	  marked	  diminution	  of	  Tfh	  differentiation[92].	  Our	  own	  studies	  did	  not	  address	  which	  cell	  type	  CTLA-­‐4	  had	  to	  be	  expressed	  on	  in	  order	  to	  control	  CD28-­‐mediated	  Tfh	  differentiation.	  	  However	  work	  from	  the	  Sakaguchi[93]	  and	  Sharpe[94]	  labs	  has	  revealed	  that	  deletion	  of	  CTLA-­‐4	  from	  the	  Treg	  population	  is	  sufficient	  to	  trigger	  increased	  Tfh	  differentiation,	  consistent	  with	  the	  idea	  that	  the	  major	  function	  of	  CTLA-­‐4	  maps	  to	  this	  population.	  	  Taken	  together,	  these	  experiments	  suggest	  that	  the	  ability	  of	  CTLA-­‐4	  to	  regulate	  CD28	  engagement	  on	  conventional	  T	  cells	  not	  only	  dictates	  whether	  or	  not	  those	  T	  cells	  will	  become	  activated,	  but	  also	  has	  implications	  for	  the	  fate	  decisions	  of	  the	  T	  cells	  post	  activation,	  notably	  their	  propensity	  to	  differentiate	  into	  Tfh.	  	  	  	  
8.	  Concluding	  remarks	  	  A	  major	  early	  research	  focus	  for	  my	  group	  was	  dissecting	  how	  Treg	  inhibit	  autoimmune	  pathology	  in	  a	  mouse	  model	  of	  diabetes.	  	  This	  led	  to	  the	  observation	  that	  CTLA-­‐4	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expression	  was	  required	  in	  the	  Treg	  population	  for	  effective	  control	  of	  T	  cell-­‐mediated	  pancreatic	  islet	  destruction.	  	  Our	  search	  for	  the	  molecular	  mechanism	  underlying	  this	  observation	  sparked	  a	  highly	  productive	  (and	  ongoing)	  collaboration	  with	  the	  Sansom	  group	  in	  which	  we	  identified	  trans-­‐endocytosis	  of	  costimulatory	  ligands	  as	  a	  mechanism	  of	  action	  for	  CTLA-­‐4.	  	  By	  limiting	  interaction	  of	  CD28	  with	  its	  ligands,	  CTLA-­‐4	  exerts	  control	  over	  all	  CD28-­‐dependent	  functions	  including	  Tfh	  differentiation	  which	  is	  highly	  sensitive	  to	  the	  level	  of	  CD28	  engagement[92].	  	  Since	  dysregulated	  Tfh	  differentiation	  is	  increasingly	  associated	  with	  autoimmune	  outcomes[95-­‐98],	  regulation	  of	  this	  process	  represents	  another	  major	  mechanism	  by	  which	  CTLA-­‐4	  protects	  from	  autoimmunity.	  	  Thus	  CTLA-­‐4	  serves	  as	  a	  key	  effector	  molecule	  in	  Treg	  where	  its	  actions	  both	  set	  the	  threshold	  for	  activation	  of	  naive	  T	  cells	  and	  influence	  the	  differentiation,	  and	  thereby	  pathogenicity,	  of	  T	  cells	  following	  activation.	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Figure	  Legends	  	  
Figure	  1.	  CD28	  and	  CTLA-­‐4:	  T	  cell	  proteins	  with	  shared	  ligands	  and	  opposing	  
functions.	  CD28	  is	  expressed	  at	  the	  T	  cell	  surface	  and	  CTLA-­‐4	  is	  predominantly	  intracellular.	  CTLA-­‐4	  is	  constitutively	  expressed	  on	  regulatory	  T	  cells	  and	  induced	  upon	  activation	  in	  conventional	  T	  cells.	  CD28	  and	  CTLA-­‐4	  bind	  to	  the	  same	  ligands,	  CD80	  and	  CD86,	  expressed	  on	  antigen	  presenting	  cells.	  	  	  
Figure	  2.	  Cell-­‐extrinsic	  function	  of	  CTLA-­‐4	  revealed	  by	  mixed	  bone	  marrow	  
chimeric	  mice.	  Rag-­‐/-­‐	  deficient	  mice	  were	  reconstituted	  with	  bone	  marrow	  from	  wildtype	  mice,	  CTLA4-­‐/-­‐	  mice,	  or	  a	  1:1	  mixture	  of	  both.	  CTLA-­‐4-­‐/-­‐	  cells	  exhibit	  hyperactivation	  and	  lymphoproliferation	  (red)	  when	  alone,	  but	  remain	  non-­‐activated	  (green)	  when	  in	  the	  presence	  of	  wildtype	  cells.	  Observation	  first	  reported	  in	  ref	  21.	  	  
Figure	  3.	  CTLA-­‐4-­‐/-­‐	  antigen-­‐specific	  Treg	  fail	  to	  control	  islet	  autoimmunity.	  i)	  Diabetes	  was	  induced	  by	  adoptively	  transferring	  OVA-­‐specific	  T	  cells	  into	  rag2-­‐/-­‐	  mice	  expressing	  OVA	  in	  pancreatic	  beta-­‐cells.	  ii)	  Co-­‐transfer	  of	  OVA-­‐specific	  Treg	  (isolated	  from	  DO11xrip-­‐mOVA/rag-­‐/-­‐	  mice)	  protected	  from	  diabetes.	  iii)	  Co-­‐transfer	  of	  CTLA4-­‐deficient	  OVA-­‐specific	  Treg	  (isolated	  from	  DO11xrip-­‐mOVA/ctla4-­‐/-­‐/rag-­‐/-­‐	  mice)	  failed	  to	  confer	  disease	  protection	  (see	  ref	  40).	  	  
Figure	  4.	  CTLA-­‐4-­‐mediated	  trans-­‐endocytosis	  removes	  costimulatory	  ligands	  from	  
APC.	  i)	  In	  the	  absence	  of	  Treg,	  APC	  can	  provide	  costimulatory	  ligands	  to	  activate	  Tconv.	  
ii)	  Treg-­‐expressed	  CTLA-­‐4	  binds	  to	  costimulatory	  ligands	  (CD80/86)	  and	  iii)	  removes	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them	  from	  the	  APC.	  This	  APC	  is	  now	  unable	  to	  provide	  costimulatory	  signals	  to	  activate	  Tconv.	  	  
Highlights	  
	  
• CTLA-­‐4	  is	  a	  critical	  negative	  regulator	  of	  the	  T	  cell	  immune	  
responses	  
• CTLA-­‐4	  can	  function	  in	  a	  cell-­‐extrinsic	  manner	  	  
• CTLA-­‐4	  is	  required	  for	  regulatory	  T	  cell	  function	  in	  certain	  
settings	  
• CTLA-­‐4	  can	  downregulate	  its	  ligands	  by	  a	  process	  of	  trans-­‐
endocytosis	  
• By	  controlling	  follicular	  helper	  T	  cell	  differentiation,	  CTLA-­‐








Figure 1. CD28 and CTLA-4: T cell proteins with 
shared ligands and opposing functions. CD28 is 
expressed at the T cell surface and CTLA-4 is 
predominantly intracellular. CTLA-4 is constitutively 
expressed on regulatory T cells and induced upon 
activation in conventional T cells. CD28 and CTLA-4 
bind to the same ligands, CD80 and CD86, 
expressed on antigen presenting cells. 	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Figure 2. Cell-extrinsic function of CTLA-4 revealed by mixed bone marrow chimeric 
mice. Rag-/- deficient mice were reconstituted with bone marrow from wildtype mice, CTLA4-/- 
mice, or a 1:1 mixture of both. CTLA-4-/- cells exhibit hyperactivation and lymphoproliferation 
(red) when alone, but remain non-activated (green) when in the presence of wildtype cells. 


























Figure 3. CTLA-4-/- antigen-specific Treg fail to control islet autoimmunity. i) Diabetes was induced 
by adoptively transferring OVA-specific T cells into rag2-/- mice expressing OVA in pancreatic beta-cells. 
ii) Co-transfer of OVA-specific Treg (isolated from DO11xrip-mOVA/rag-/- mice) protected from diabetes. 
iii) Co-transfer of CTLA4-deficient OVA-specific Treg (isolated from DO11xrip-mOVA/ctla4-/-/rag-/- mice) 



































APC Figure 4. CTLA-4-mediated trans-endocytosis removes costimulatory ligands from APC. i) In 
the absence of Treg, APC can provide 
costimulatory ligands to activate Tconv. ii) Treg-
expressed CTLA-4 binds to costimulatory ligands 
(CD80/86) and iii) removes them from the APC. 
This APC is now unable to provide costimulatory 
signals to activate Tconv.	  
